MYGN Myriad Genetics Inc.

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences.

  • The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.



  • The 37th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET.

The presentations will be available through live audio webcast links in the investor information section of Myriad’s website at . 

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit .

Investor Contact 

Matt Scalo 

(801) 584-3532 

 

Media Contact 

Kate Schraml

(224) 875-4493



EN
11/11/2025

Underlying

MYGNMyriad Genetics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study...

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026 SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and highlighted compelling data that reinforces the clinical value of ultrasensitive circulating tumor DNA (ctDNA) detection across cancer types. Myriad will launch Precise MRD with select...

January 27, 2026 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Y...

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the ...

January 12, 2026 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Confe...

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET). The presentation will be available through a live webcast and archived at .  About Myriad Genetics  Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated t...

January 5, 2026 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at ...

Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the ® (SABCS). The company will share the latest advances in the that support guideline-driven treatment decisions. Additionally, the company is presenting data on its , an ul...

December 9, 2025 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI ...

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health Actionable offering helps enable earlier, more personalized breast cancer interventions BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) --   (NASDAQ: MYGN), and , today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens. The agreement brings together three leader...

November 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch